HBA honorees share stories and advice

Share this article:
The Healthcare Businesswomen’s Association’s top awardee said biotechnology’s pioneers, who started with “little more than some great science and a dream,” offer a prototype for today’s leaders. “That dreaminess, hope, promise and passion to do something that’s never been done before … is a great thing,” said Susan Desmond-Hellmann, recipient of the Woman of the Year Award from the HBA. Desmond-Hellmann, Genentech president, product development, has spent a decade in biotechnology, all of it with the South San Francisco firm. Also receiving awards at the New York luncheon were HBA’s honorable mentor, Matthew Emmens, who is CEO of Shire Pharmaceuticals, and Sharon Callahan, president of Summit Gray, who received the star volunteer award. Desmond-Hellmann offered her keys to leadership, which include being flexible and confident while not being afraid to take a risk. She urged the 1,700 attendees to “be relentless” in pursuing goals. Her focus while at Genentech has centered on approving drugs to treat cancer. In case anyone looks to The Apprentice as a guidebook for succeeding in business, Shire’s Emmens offered some advice of his own. “Pitting people against each other doesn’t work,” he said, referring to a recent episode of the show that featured a test of wills between a team composed of women and one of men. The women won, but the two camps could have worked together to greater effect. “Women bring to the table a different view, compassion, sensitivity, creativity,” he said. “Whenever [Trump] mentions ‘team,’ I cringe.”
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Channel

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...